NCT01083615 2016-10-12A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Achieve Life SciencesPhase 3 Terminated14 enrolled